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Abstract
A photodynamic effect occurs when photosensitiser molecules absorb light and dissipate the absorbed energy by transferring 
it to biological acceptors (usually oxygen), generating an excess of reactive species that are able to force cells into death path-
ways. Several tropical diseases present physiopathological aspects that are accessible to the application of a photosensitiser 
and local illumination. In addition, disease may be transmitted through infected blood donations, and many of the aetiological 
agents associated with tropical diseases have been shown to be susceptible to the photodynamic approach. However, there has 
been no systematic investigation of the application of photoantimicrobial agents in the various presentations, whether to human 
disease or to the disinfection of blood products or even as photo-insecticides. We aim in this review to report the advances in 
the photoantimicrobial approach that are beneficial to the field of anti-parasite therapy and also have the potential to facilitate 
the development of low-cost/high-efficiency protocols for underserved populations. 
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Tropical diseases (TD) are clinical conditions caused by 
microbial infections, usually limited geographically to tropical 
areas. TD can cause exotic symptoms that have been noted 
by travellers, explorers, and physicians for many years but 
that were initially not found in western civilization. The trop-
ics present a series of environmental (wet climate, higher 
temperature, animal reservoirs, insect vectors) and socio-
economic factors (water treatment, sanitary conditions) 
that favour the development of these diseases. Estimates 
suggest that there may be about 0.5 million of deaths per 
year due to TD, not including malaria (1).
There is also an enormous related socio-economic 
burden with millions of people having to deal with diseases 
that hinder a proper quality of life. In addition, globalisation 
has increased the potential danger that an exotic micro-
bial disease may be introduced into a new setting where 
there is no natural resistance. The situation for malaria 
is somewhat different, being already a threat to millions 
of travellers from richer economies that require efficient 
prophylaxis, besides killing millions of humans annually. 
Funding of scientific investigation related to tropical medicine 
has improved markedly in recent years due to industrial as 
well as government-backed research. However, the com-
plexity of the diseases in terms of the different life forms of 
the pathogens and their interactions with the host immune 
system, different vectors etc., present continual challenges 
in terms of the development of new selective drugs. Find-
ing specific targets in these pathogens has proved to be 
difficult. An important question still remains: how much 
more time will be required for effective modern medicines 
to be supplied for diseases such as trypanosomiasis and 
leishmaniasis? (2).
One characteristic of the pathogens that cause these 
diseases is the fact that they live together with the host 
organisms for many years, having to deal with their im-
mune systems in general and especially with the oxidative 
artillery of the host. In fact, redox equilibrium is a key issue 
related to the survival/death balance of the parasite/host 
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interaction. It is not surprising, therefore, that the majority 
of the antiparasitic drugs available in the market work by 
affecting parasite redox systems (3,4). 
One of the most effective ways that is known to cause 
redox imbalance in cells is the use of photoactivation (5). 
Based on mechanistic evaluation and available literature 
data, we will show that photodynamic processes offer a 
great opportunity for the development of new drugs for 
controlling TD on several fronts, including reducing parasite 
infection in the hosts as well as providing alternatives for 
blood disinfection and vector control.
In terms of healing properties, the application of photo-
sensitisers to TD is likely to be of greatest utility where there 
is either a skin or a soft tissue manifestation of the disease. 
Because photodynamic antimicrobial chemotherapy (PACT) 
is dependent upon exposure to a directed light source, it al-
lows local treatment and control, but consequently cannot af-
fect advanced, disseminated diseases (5,6). Conversely, no 
microorganism resistance has been reported against PACT, 
and the low cost of commonly available photosensitisers, 
coupled with the availability of inexpensive low-power light 
sources, suggests that this approach is of great potential 
healthcare benefit in TD (5,6). Although the first published 
result of photosensitisation applied in biology was an obser-
vation made by Raab (7) at the beginning of the last century 
of the photo-induced killing of Paramecium caudatum, the 
potential use of PACT to kill parasites and control TD has 
not yet been even moderately exploited. Consequently, 
the present study is based on the potential application of 
photoantimicrobial approaches to leishmaniasis, malaria, 
and African and American trypanosomiases.
As noted above, the light requirement means that 
the treatment of disseminated diseases is not feasible at 
present. However, the application of PACT to blood prod-
uct disinfection offers considerable potential in blocking 
TD transmission, and this is also covered in the current 
study.
Photosensitisers: fundamentals and state 
of the art
Light absorption by organic molecules is essential to 
life, allowing the photosynthetic pathway in plants via the 
photoexcitation of chlorophylls and related pigments (8). 
Although photosynthesis has an excellent yield of light to 
chemical energy conversion, side processes compete with 
normal electron transfer reactions favouring the production 
of reactive oxygen species (ROS) and nitrogen oxygen spe-
cies (RNS) (9,10). These species damage biomolecules, 
causing photoinhibition and photodestruction of the pho-
tosynthetic apparatus. In humans, similar photoprocesses 
are related to premature photoaging and skin cancer, while 
lower organisms have also evolved the use of photoreac-
tions to protect themselves (4). In plants, photoantimicrobi-
als are used as chemical defence weapons against attack 
by herbivorous insects, and the strategy is also used by 
parasitic fungi to help break plant cell walls (6).
Photodynamic antimicrobial chemotherapy is a thera-
peutic modality based on the combination of a photosen-
sitiser that is selectively localized in the target tissue and 
illumination of the area of interest, usually with visible light, 
resulting in photodamage and cell death (5,6). Exposure of 
a photosensitiser to light of a specific wavelength will lead 
to light absorption, the production of excited species and 
ultimately the transfer of this excitation energy to oxygen to 
generate ROS (11). The excited species (especially triplet 
species) transfer energy to oxygen (type II photosensitisa-
tion), or undergo direct reaction (electron transfer or other 
reactions) with the target substrates (type I photosensitisa-
tion), usually generating radicals and finally ROS (Figure 
1) (11). In addition to causing cell death, photosensitisation 
reactions in biological tissues can also induce immune 
stimulatory reactions (12,13), and consequently have the 
potential to improve the overall host response to infec-
tions (3). However, under mild conditions, oxygen does 
not react with electron pairs of organic molecules in the 
ground state. Consequently, most organic molecules must 
be transformed into radical species before they can react 
with molecular oxygen. A catalyst that allows one-electron 
reactions is, therefore, necessary to promote the oxidation 
of biomolecules. The stepwise one-electron reduction of 
oxygen produces the anion radical superoxide, hydrogen 
peroxide and the hydroxyl radical, which is one of the most 
reactive molecules known (11). The reactivity of oxygen 
can also be dramatically increased by elevating it to the 
excited state (singlet oxygen), allowing it to add to double 
bonds of biomolecules. Ideally, photosensitisers should 
act via both type I and type II mechanisms to increase the 
range of ROS that can be generated; however, in the pres-
ence of biological molecules and interfaces there can be a 
Figure 1. Electron and energy transfer reactions in which meth-
ylene blue (MB) is involved in the presence (above) and in the 
presence and absence of light (below). PS is photosensitiser in 
the singlet (1PS) and triplet (3PS) excited states; 3O2 and 1O2 are 
the ground and excited (singlet) states of molecular oxygen (O2). 
PS. is the reduced species of PS, and O2.- is the anion radical 
superoxide.
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competition between type I and type II mechanisms (14). 
Methylene blue and other phenothiazinium derivatives are 
examples of photosensitisers that work both by type I and 
type II mechanisms (14,15). 
Some photosensitisers, including phenothiaziniums 
and triarylmethanes (e.g., crystal violet, CV) can also be 
reduced in the dark in the biological environment. The 
reduction may be directly from reduced co-enzymes, in 
the case of methylene blue (E1/2 = -0.28 V), for example, 
the reduction potential being lower than that of NADH 
(E1/2 = -0.32 V) (16). Conversely, it can involve reduction 
in the electron chain reactions. Reoxidation may involve 
direct reaction with oxygen, forming the superoxide anion 
radical. Enzymatic oxidation by enzymes in the electron 
chain is also possible, in such a way that the photosen-
sitisers work as a bypass in the electron chain reactions. 
Depending on the quantities involved, this interference in 
the redox cellular cycle can help cells to survive a possible 
mitochondrial dysfunction or, at higher concentrations, a 
redox imbalance may be induced, damaging cells. This 
explains why molecules such as CV may also be used in 
disinfection strategies in the dark. In fact, the induction of 
redox imbalance was used to explain the bacteriostatic and 
bactericidal activity of CV against B. subtilis, E. coli, Str. 
lactis, and S. marcescens as early as 1933 (17). The authors 
also reported that ~90% of all Gram-positive strains and 
only 10% of Gram-negative strains were susceptible. CV 
is currently frequently employed for this purpose in blood 
products without photoactivation (18). It is important to 
mention that the microorganism killing efficiency of CV and 
other similar molecules in the dark is amplified several times 
under photoactivation, explaining the promissory strategy 
of using them as photomicrobicides (5,6,19).
The amount of energy needed to promote an electron 
from the ground to the excited state (Figure 1) depends on 
the molecular structure of the photosensitiser. Therefore, the 
wavelength of light causing the electronic promotion is also 
highly relevant in the application of the photosensitiser (19). 
Because of the range of molecular structures of available 
photosensitisers there is a corresponding array of activation 
wavelengths, from ultraviolet, through visible, to near infra-
red. Similarly, there are various biomolecules, which absorb 
electromagnetic radiation from UV to the visible region, 
competing with the photosensitisers for the excitation light. 
Besides light absorption, light scattering is another process 
that decreases the amount of light penetration in the biologi-
cal tissues, and the amount of light scattered decreases as 
the wavelength of light increases (19). Such interferences 
have been the main drivers towards the development of 
long-wavelength absorbing photosensitisers absorbing far 
red or near infrared radiation (5,6,15,19,20). 
As noted above, the redox balance of cells infected by 
parasites is a critical issue in the progression of the para-
site infection. In fact several drugs in use today are based 
on the generation of an intracellular ROS burst that either 
kills the parasite or the infected host cell (3). Research 
in the area of photoactivation reactions in the biological 
environment has progressed in such a way that certain 
molecular structures are known to favour photosensitiser 
localisation in different environments of cells, thus having a 
significant impact on the mechanism and efficiency of cell 
death (21,22). Photosensitisers that localize in mitochondria, 
lysosomes, and nuclei and bind efficiently to membranes 
have been characterized and a great deal of information 
concerning structure-activity relationships has been uncov-
ered (15,21-26). The distribution of polar and hydrophobic 
substituents around the central chemical structure of the 
photosensitiser, the electronic charge of side chains, and 
chelation by the central amino groups are all molecular 
features that seem to play significant roles (23-25). Cationic 
(positively charged) photosensitisers may be especially 
effective clinical agents because they can accumulate in 
negatively charged surfaces including mitochondria (21,23-
25), an effect that is driven by the transmembrane potential 
of the inner mitochondrial membrane (16). Therefore, it is 
possible to design molecules that could have a significant 
impact on the host-parasite relationships leading to the 
cure or control of these diseases, although the rationale 
for targeting parasite cells inside host cells has not been 
obtained so far. It should also be emphasized at this point 
that the major selectivity exhibited by photosensitisers must 
be that between host and target cells. 
Photoantimicrobials
In photodynamic therapy (PDT), the anticancer ap-
proach related to PACT, the photosensitisers employed 
clinically are generally based on the porphyrin nucleus, 
mainly for historical reasons (27). This situation is changing 
rapidly since new inexpensive protocols are being developed 
based on phenothiaziniums, hypericin and triarylmethanes 
(15). In the case of PACT, the range of molecules considered 
since its origin is much wider.
The early history of chemotherapy is closely linked 
with the work of Paul Ehrlich. Indeed, he devised the term 
“chemotherapy”. Ehrlich’s research was mainly involved with 
the differential staining of cells using aniline-derived dyes. A 
major part of Ehrlich’s time was spent examining stains for 
parasites encountered in TD. His work led to widely used 
stains such as Trypan red and Trypan blue, and the drugs 
that were developed from them (5-7).
The development of PACT may be envisaged as an 
extension of Ehrlich’s work, in the sense that several of 
the photosensitisers in use are, in fact, biological stains. 
Interestingly, the chemical structure of stains such as meth-
ylene blue provided the lead compounds to conventional 
chemotherapeutic agents, such as aminoquinoline and 
acrydine antimalarials, e.g., chloroquine and mepacrine, 
respectively (6). 
Photoantimicrobial action, i.e., the effect of the gen-
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eration of large amounts of ROS such as singlet oxygen 
or the hydroxyl radical on microbial species, is extremely 
destructive for two main reasons: lack of effective microbial 
defensive mechanisms and multiple sites of attack (5,6). 
Although cells have several natural defences against ROS, 
the level of redox imbalance inflicted by PACT is several 
orders of magnitude larger than the level or protection al-
lowed by enzymatic and molecular antioxidant species in the 
cell. Besides, antioxidant cellular enzymes such as catalase 
and superoxide dismutase are inactivated by singlet oxygen 
(27). It is important to mention that in the photoactivation 
reaction, different ROS with different mechanisms and differ-
ent action sites are generated, resulting in multiple sites of 
attack on the microorganisms. Consequently, an important 
benefit of PACT is the absence of microbial resistance and, 
thus, a similar efficacy against conventional drug-sensitive 
and drug-resistant microbial strains. The multifactorial attack 
of photoantimicrobial agents has been demonstrated, for 
example, in both viruses and bacteria (5,6,26,27). 
Just as antimicrobial agents have a wide range of 
chemical forms - β-lactams, tetracyclines, fluoroquinolo-
nes, etc., so there is no single chromophoric group, which 
can be used in photoantimicrobials. Such agents (Figure 
2) may belong to the porphyrin, phthalocyanine, azine, 
triarylmethane, or cyanine families. The effectiveness 
of a photo-decontamination depends on a series of fac-
tors including the type of microorganisms as well as the 
type of photosensitisers and the reaction medium. It is 
often relatively straightforward to demonstrate microbial 
selectivity, given the biological staining heritage of many 
photoantimicrobial agents (5,6,27-29). 
Since photoantimicrobial drug development may be 
carried out following the same principles as used for con-
ventional drugs - i.e., new compound generation based on a 
lead structure - although there is a range of structural types, 
it is not enormous. To use methylene blue as an example, 
its broad-spectrum activity as a photobactericidal agent has 
been accredited to the cationic nature of the chromophore, 
with other, anionic or neutral photosensitisers being essen-
tially inactive against Gram-negative bacteria (29). However, 
where cell penetration is required, the hydrophilic nature 
of methylene blue is disadvantageous, and more lipophilic 
molecules may be more successful - for example in intracel-
lular virus inactivation in red blood cells (30). Among several 
physical and chemical properties tested, the affinity of a 
specific photosensitiser for viral nucleic acid seems to best 
correlate with its virus photokilling efficiency (31). 
Considerations in the control of tropical 
diseases
In terms of developing effective treatments against a 
specific TD in endemic areas it is important to think about 
all strategies that would favour a decrease in the pool of in-
fected patients (32). Developing an efficient clinical protocol 
that would cure/control the disease would not only favour 
the patient, but would also decrease the chance that this 
infection would be transmitted to others by the usual vec-
tors or via blood transfusion. The following sections cover 
the potential for use of PACT in the treatment of malaria, 
leishmaniasis and trypanosomiasis. However, it is also 
important to consider strategies in which photoactivated 
compounds can be employed in blood product disinfection 
and in the direct control of vector dissemination.
Blood product disinfection
Whole blood is a mixture of three main fractions: plasma, 
platelets and red blood cells. There are also therapeutic 
proteins, such as clotting factors (e.g., Factor VIII). Each 
of these, and whole blood itself, finds use in haematologi-
cal replacement - whether in volume, due to blood loss, 
or in the treatment of a deficiency syndrome, such as 
haemophilia.
Since the establishment of the germ theory of infectious 
disease, it has been appreciated that the spread of illness 
within an individual is closely tied to the circulatory system. 
By extension, then, the use of blood in transfusion or of 
blood products in therapy must be subject to very strict 
controls in order to avoid the transmission of infective agents 
between donor and recipient. This is further complicated 
by the practice of “pooling” of blood fractions from multiple 
donors in order to facilitate supply.
Clearly, the examination, or screening, of donated blood 
is necessary in order to minimise transfusion-transmission 
events. However, such screening has significant cost impli-
Figure 2. Chemical structures of the principal photosensitisers 
relevant to tropical diseases.
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cations and is thus not carried out universally. In addition, 
practical screening does not exist for all common infective 
agents, and there is the additional problem of emerging 
pathogens/diseases.
In order to guarantee the freedom of blood products 
from pathogenic microbes, various eradicative treatments 
have been proposed, including solvent-detergent treatment 
and ultraviolet irradiation. Most treatments appear to have 
associated collateral effects. The use of photosensitisers 
to this end represents a logical step, since blood fractions 
may be illuminated “in the bag” on a light table or similar 
apparatus. This is possibly the most important aspect of 
PACT in relation to TD transmission, as will be understood 
from the following sections, since there are important TD, 
which are systemic in the main and thus not, at present, 
susceptible to the photodynamic approach (33). 
The main challenge in blood disinfection is to kill 
or inactivate the target microorganism without harming 
blood cells or serum proteins. Reinfusion of damaged 
blood products, besides not being effective in the patient, 
can actually be harmful and cause an immune response. 
Conventional methods of disinfection include the use of 
chemotherapeutic agents, some of which have the potential 
to be used as photosensitisers. As mentioned above, CV 
is one example.
The main advantage of PACT is its multi-target nature, 
being potentially efficient against viruses, bacteria, fungi, 
and parasites. As with any other strategy of blood disinfec-
tion, there is the potential host toxicity of the photosensi-
tisers. Either all of the photosensitiser must be removed 
from the treated material prior to transfusion or it must be 
non-toxic to the recipient. In fact, the majority of the photo-
sensitisers that have been used for blood disinfection are 
non-toxic (methylene blue, crystal violet, riboflavin). Strate-
gies based on PACT to promote pathogen inactivation in 
stem cells from cord blood have been proposed (6,34). Even 
so, strategies aiming to separate photosensitisers from the 
treated blood, for instance using magnetic nanoparticles, or 
strategies that would allow the photosensitisation reaction 
to occur without the direct contact of the photosensitiser 
with blood (for example, photosensitising surfaces) would 
possibly allow new and more efficient methods of blood 
disinfection. 
Methylene blue has been used widely as a photo-
sensitiser for blood product disinfection. Using dry pills 
of methylene blue, plasma containing the agent (1 µM) 
is prepared and illuminated at 590 nm. Methylene blue is 
then separated from the blood using a special depletion 
filter through which the treated blood product is passed into 
storage bags. Methylene blue and similar compounds that 
bind preferentially to nucleic acids or to specific intracel-
lular organelles, in principle, could permit the elimination of 
nucleate cells (of infecting agents) or viruses. In reality the 
widespread use of PACT to treat whole blood is awaiting 
strategies that would allow greater selectivity for infecting 
agents, saving red blood cells from being damaged in the 
photoactivation process (6,33). 
Although in use for almost 20 years as a plasma dis-
infectant agent, methylene blue does not seem to be an 
ideal photosensitiser for this application due to collateral 
damage, typically to clotting agents. This damage is likely 
to be due to the tendency of the agent to damage lipids. 
Similar photosensitisers, which are either more or less polar 
than methylene blue, seem to be better suited as blood 
photodisinfection agents. Thionin, the demethylated deriva-
tive of methylene blue, has been shown to be as efficient 
as the latter as a photokilling agent, without damaging red 
blood cells and platelets (27,29,33). 
One of the protocols used in the pathogenic inactiva-
tion of blood products involves irradiation using UV light. 
UV is by itself a potent microbicidal agent; however, it is 
also damaging to several blood components. Addition 
of riboflavin prevents the side effects of UV, like red cell 
haemolysis and oxidation of haemoglobin to the methae-
moglobin, while maintaining the photokilling of microbial 
organisms. In addition to being a vitamin (vitamin B2), 
riboflavin is a potent photosensitiser, acting both as a type 
I and type II mechanism. Because it does not have a formal 
charge on its structure, it does not interact strongly with 
proteins or charged membranes and biomolecules, which 
probably explains the low level of biomolecular damage. 
Riboflavin is also inherently non-toxic and does not need 
to be removed after the decontamination process. There-
fore, riboflavin shows great promise as a decontamination 
agent (34,35). 
Malaria
Mosquito-borne diseases are transmitted via the blood 
of bitten individuals. In the case of malaria, the infective 
agent, Plasmodium spp, is injected through the mouthparts 
of female anopheline mosquitoes and has a life cycle in hu-
mans, which includes both bloodstream and tissue phases. 
There are several infective members of the Plasmodium 
genus. The most serious is P. falciparum, with less seri-
ous disease caused by P. ovale, P. vivax and P. malariae. 
Relapsing fevers are often encountered with infection by 
P. knowlesi.
The discovery of the links between mosquitoes, plasmo-
dia and malaria was made over a century ago. Confirmation 
of the parasite in the bloodstream was made by staining 
patient blood smears. The stains used were cationic dyes 
such as methylene blue and the demethylated azures. The 
selectivity exhibited in this way led one of the founders of 
antimicrobial chemotherapy, Paul Ehrlich, to use methylene 
blue as a treatment for the disease, curing two sailors of 
malaria in 1891 (36). 
The fact that stains such as methylene blue are taken 
up by plasmodial cells inside erythrocytes relative to unin-
fected erythrocytes demonstrates the damage caused to 
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the red cell membrane by the parasite, since hydrophilic 
cations are normally excluded (37). A similar argument is 
made for the concentration of aminoquinoline antimalarial 
drugs by infected red blood cells.
PACT may be seen as an application of Ehrlich’s ap-
proach - several of the photosensitisers proposed for use 
are, in fact, biological stains, thus exhibiting selectivity 
for parasites in the first instance. Indeed, methylene blue 
provided the lead compound from which the aminoquino-
line and acrydine antimalarials - chloroquine, mepacrine, 
etc. - were developed (6,7,27,29,33). In recent years, 
methylene blue has undergone re-evaluation as a clinical 
antimalarial (27), this representing use as a traditional, 
not a photodynamic, drug. However, the acceptance of an 
intensely coloured, systemic therapeutic agent has been 
reportedly high despite the obvious sequelae of coloured 
urine and stools.
Guttmann and Ehrlich’s successful demonstration of the 
antimalarial nature of methylene blue was followed by its 
use as lead structure in many early areas of drug research, 
not merely tropical medicine (38). However, several close 
analogues have been shown to be active against the ma-
larial parasite (39), and several of these have also been 
examined for blood product decontamination protocols (40). 
Such work is given special significance by the increasing 
problem of malarial chloroquine resistance.
As discussed above, the use of photosensitisers as 
antimicrobial agents relies on the production of ROS 
inside or in close proximity to the target cell. Plainly the 
demonstrable selectivity of the phenothiazinium stains 
for plasmodia coupled with established photosensitising 
activity suggests the use of such compounds against para-
sitic infection. However, given the location of the malarial 
parasite in the human body - i.e., the blood stream or the 
liver - it is difficult to see, at present, how a direct treatment 
protocol could be achieved. Theoretically, at least, it should 
be possible to attack the liver stage via implanted optical 
fibres, but this would be considered to be relatively high 
risk. Attacking the parasite in the bloodstream is likewise 
problematic from the point of view of effective illumination 
of the blood circulation. However, the transmission of ma-
laria via donated blood may be addressed using currently 
available technology and approaches.
Other photosensitisers examined in terms of pathogen 
inactivation for use in blood products include the cationic 
silicon phthalocyanine mentioned above (Figure 2). This has 
been shown to photoinactivate P. falciparum (41,42). 
Cutaneous leishmaniasis
Leishmaniasis is an important disease in public health 
with about 600,000 new cases per year. Worldwide there 
are about of 12 million people infected with Leishmania 
ssp parasites (43). The parasite is spread by the bite of an 
infected sand fly and can cause disfiguring and sometimes 
fatal diseases. The parasite has different life forms in the 
human host and in sand fly vectors, i.e., amastigotes, which 
are small and oval and promastigotes, which are longer 
flagellated forms of the parasite. Domestic dogs are also 
infected by Leishmania parasites and these animals are a 
reservoir for human leishmaniasis (44).
There are many different diseases caused by Leish-
mania spp. When the parasites do not spread beyond 
the site of the vector’s bite, this may result in cutaneous 
leishmaniasis. In other instances the amastigotes may 
spread to the liver or spleen, resulting in visceral leish-
maniasis, or to the mucous membranes of the mouth and 
nose, resulting in mucocutaneous leishmaniasis. Left 
untreated, these latter diseases result in high rates of 
mortality, although the use of antimony-containing com-
pounds usually gives good results. The various types of 
leishmaniasis are confined primarily, but not exclusively, 
to Central and South America, central Africa, and parts of 
southern and central Asia (45).
When Leishmania parasites first enter the human body, 
promastigotes are engulfed by macrophages but are re-
sistant to proteolysis and degradation in the phagosome. 
Once inside the macrophage, the parasite is named an 
amastigote. By continuing to live inside the macrophage, 
Leishmania amastigotes effectively avoid the humoral 
branch of the immune system. The parasite invasion into 
the macrophages is an extremely sophisticated process, 
in which the parasite presents in its exterior phosphatidyl-
serine, simulating the condition of apoptosis and inducing 
phagocytosis by the macrophage (46). After being engulfed, 
the Leishmania parasites must endure harsh conditions 
inside the phagosome. For example, the macrophage uses 
an oxidative burst (ROS, superoxide and hydroxyl radicals) 
and RNS, i.e., nitric oxide to destroy foreign material in the 
phagosome (47). The host-parasite relation for Leishmania 
spp involves three important characteristics: suppression/
protection of the parasite from the ROS and RNS cell de-
fences, control of the host apoptosis process and protection 
against the host immune response. All of these aspects can 
be neutralised by PACT. 
The defence mechanism of the intracellular parasite 
against oxidative stress involves efficient production of 
reducing agents. This is true for Leishmania spp and also 
for other parasites such as P. falciparum. In both cases, 
the main treatment involves the uses of drugs that cause 
an imbalance in the cell redox state to the oxidation side, 
preventing parasite multiplication (48). For instance, the 
potentiation of ROS and RNS formation by sodium sti-
bogluconate (Pentostam), one of the drugs used to treat 
leishmaniasis, was recently described (49). The mechanism 
by which these reactive radical species produced by the 
macrophages are neutralised involves glutathione (GSH) 
or trypanothione (the GSH analogue in the Leishmania 
spp thiol recycling system), using NADPH as reductant, 
formed in the pentose shunt (3). Therefore, the inhibition of 
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enzymes related to the control of the redox states in the cells, 
including glutathione reductase and glucose-6-phosphase 
dehydrogenase, offers a potential mode of attack against 
the intracellular parasite.
Current treatment of leishmaniasis is limited to pen-
tavalent antimony derivatives, amphotericin B, and paro-
momycin, which can cause serious side effects. Other 
serious drawbacks associated with these medications 
are the complexity of the treatment protocols and their 
high cost, making them unsuitable for the majority of 
underserved populations afflicted by such disease. In ad-
dition, the limited number of medications for a widespread 
population has also created drug resistance; in fact, 60% 
of leishmaniasis cases have been reported to be resistant 
to first-line drugs (49). 
Due to the clinical efficacy of PDT in localised cutaneous 
disease and the growing evidence of photoantimicrobial 
activity, researchers have begun limited clinical trials of 
PDT to treat cutaneous leishmaniasis and have observed 
interesting results. 5-Aminolaevulinic acid (ALA) is cur-
rently a popular PDT prodrug, being metabolised by both 
mammalian and microbial cells to the photosensitiser pro-
toporphyrin IX as part of the heme biosynthetic pathway 
(50). ALA and subsequent red light illumination have been 
used to treat patients in the Middle East and Europe with old 
world cutaneous leishmaniasis (L. major). These patients 
achieved a greater than 90% cure rate without evidence of 
recurrence (51). However, the cost of ALA remains prohibi-
tive and largely inaccessible to the populations in need. 
Corroborating the clinical studies, Kosaka et al. (52) showed 
a 25-fold decrease in parasite load in infected mice after 
one PDT treatment. Importantly, they concluded that the 
parasiticidal effect of PDT observed was probably mediated 
via the indirect killing of infected host cells and not through 
direct parasite killing. Protoporphyrin IX accumulates within 
the parasite, probably through an endocytic internalization 
pathway - although this mechanism has not yet been stud-
ied - but in amounts insufficient for phototoxicity. 
Thus, it is imperative to study the efficacy of PDT against 
leishmaniasis using photosensitisers that are directly effec-
tive against the parasite. In fact, Kosaka and co-workers 
(52) have provided evidence that positively charged pho-
tosensitisers are extremely effective in this respect, as 
have Bristow et al. (53) using a series of positively charged 
porphyrins. However, remembering the financial implica-
tions of treatment programmes in impoverished regions, 
a low-cost PDT protocol, based on the administration of 
methylene blue plus irradiation with a non-coherent light 
source, has been shown to be effective against L. ama-
zonensis parasites in vitro and in vivo. Given the absence 
of methylene blue toxicity in humans, the local application 
of the photosensitiser and illumination of cutaneous lesions 
of leishmaniasis should be effective against the parasites, 
including those strains against which conventional therapies 
are ineffective. 
Trypanosomiasis
After malaria, African trypanosomiasis was the principal 
disease studied by Paul Ehrlich with his application of dyes 
to stain infected cells. As noted above, this led to the devel-
opment of the drug suramin from the azoic dyes trypan red, 
trypan blue, etc., such dyes being effective against rodent 
models of the disease but not in humans.
Human African trypanosomiasis, caused by the intro-
duction of Trypanosoma brucei gambiense or T. brucei 
rhodesiense during biting by the tsetse fly, is usually a 
disease of the nervous system, sleeping sickness. Con-
versely, American trypanosomiasis, or Chagas’ disease, is 
normally caused by infection with T. cruzi. Neither disease 
has a significant dermatological aspect (except the puncture 
wound caused by the biting insect disease vector), but in-
fected persons carry the protozoa in the bloodstream. Thus, 
although neither the African nor the American form has a 
locally approachable focus, the causative organisms for both 
should be targeted as part of blood disinfection protocols. 
T. cruzi has been included in proposed photodisinfection 
protocols, and the photokilling of the organism has again 
been demonstrated with the silicon phthalocyanine Pc4 
(Figure 2), and thiazole orange (54). As mentioned above, 
crystal violet is already employed for the inactivation of T. 
cruzi in donated blood, and this also offers a strong poten-
tial lead for conventional drug discovery against T. cruzi. 
Earlier experimentation by Do Campo and co-authors (18) 
using T. brucei in citrated guinea pig blood demonstrated 
that the parasites could be immobilised by a 1% solution of 
methylene blue or by a 0.001% solution in conjunction with 
white light illumination from a 100 W source, the immobilised 
organisms causing no subsequent disease in mice. 
Additionally, the redox dyes brilliant cresyl blue, a phe-
noxazine derivative, and the phenothiazinium new meth-
ylene blue have been shown to be inherently trypanocidal 
- i.e., without light activation - in infected macrophages. 
This reflects the influence of the redox properties of both 
dyes on the parasite. Dyes must pass into the interior of the 
macrophage before killing the parasite. The capacity that 
some molecules may have of entering host cells without 
damaging them, and targeting microbial parasitic cells inside 
the host cell, provides a reasonable hypothesis on which 
to model blood cell disinfection. As discussed above, in 
blood disinfection strategies it is important to cause specific 
damage to parasites without affecting host cells (55). The 
increased efficiency of singlet oxygen production by new 
methylene blue, in comparison to that of methylene blue 
itself is another promising factor in the search for effective 
photoantimicrobial agents (56).
It should also be noted that the ultraviolet-absorbing 
Amotosalen (4’-aminomethyl-4,5’,8-trimethylpsoralen) has 
been reported to give complete inactivation of the infective 
form of T. cruzi both in fresh-frozen plasma and in platelet 
concentrates (57). Rationally, given the severity of disease 
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associated with trypanosome infection, it is important that 
such agents are removed from the blood supply. However, 
most blood industry concerns did not screen for the various 
trypanosomes until relatively recently. Indeed, there was 
no standard test available until 2007. 
Vector control
The dissemination of TD is strongly influenced by insects 
since these are the main vectors transmitting the pathogens 
from one individual to another. Due to deforestation, insect 
vectors invade cities and are thus considered responsible 
for establishing new endemic regions of disease. Govern-
ments around the world spend significant resources on the 
control of insect vectors, usually entailing the use of chemi-
cal insecticides, which are known to cause side effects in 
the population and are harmful to the environment. Other 
strategies have been devised including biological control 
and photoinsecticides.
Photoactivated insecticides were shown to be an in-
teresting alternative to chemical insecticides. Usually they 
can be used at low concentration, because they use light 
energy to “catalytically” generate toxicity. Besides being 
used at lower concentrations, photoactivated insecticides 
may be intrinsically less toxic to the environment. First of 
all they are non-toxic in the dark and second they are less 
prone to accumulate, because they are usually bleached 
and further degraded by light. The concept of using pho-
tosensitisers to control pest populations was realized as 
early as in the 1930’s using xanthene derivatives against 
Anopheles and Aedes larvae (58). The developments in 
this field have been reviewed by Ben Amor and Jori (59). 
Porphyrins are particularly interesting as photoinsecticides 
because they exhibit several absorption bands in the UV/
visible spectrum, being therefore efficiently excited by 
the solar spectrum. The photoactivity efficiency seems to 
depend both on the octanol/water partition coefficient of 
the photosensitisers and on specific structural features 
such as the amphiphilic character (60). In general terms, 
the efficiency of binding to the membranes seems to be a 
key factor to explain efficiency of photo-activity. Efficiency 
of membrane binding can be related to both the value of 
the octanol/water partition coefficient and to the optimised 
structural matches that allow their incorporation within the 
membrane (23,60). 
Conclusions
Major TD such as malaria, leishmaniasis and trypanoso-
miasis constitute significant morbidity and mortality, mainly 
in the developing world. Given the size of the problem, with 
many millions of infected people, the task of providing ef-
fective healthcare is often unachievable, both on grounds 
of the funding available and also the absence of useful 
therapeutic regimens. However, recent developments in 
photoantimicrobials offer considerable potential for use in 
TD where local application of drug and light are feasible, 
e.g., in presentations such as cutaneous leishmaniasis. 
This is particularly appealing where relatively inexpensive 
photosensitisers, such as methylene blue and crystal violet, 
have been shown to be effective.
The application of photoantimicrobials to blood product 
disinfection also offers considerable potential in infec-
tion control. As crystal violet is already employed in the 
(non-illuminated) inactivation of T. cruzi by various blood 
collection agencies, the move to photodecontamination 
would not constitute a quantum leap. In addition, the use of 
other photosensitisers, such as methylene blue, is already 
widespread in Europe, thus providing evidence of efficacy 
and available technology.
The topical/local approach to tropical disease and 
pathogen inactivation in the blood supply are not claimed 
to be an answer to the problem of TD. However, both con-
stitute possible additions to the current therapeutic arsenal, 
with added value where conventional drug resistance is 
encountered.
As in the case of any therapeutic modality, better knowl-
edge of the mechanisms of action can allow improvements 
in terms of sensitivity and selectivity. We believe that the 
development of more robust photosensitizers based on 
better understanding of specific action mechanisms could 
allow an increased role of PACT in the treatment and 
control of TD.
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